Trials / Completed
CompletedNCT00731081
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
Observational Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe severe late onset patients with pompe disease receiving Myozyme®
Conditions
- Pompe Disease (Late-Onset)
- Glycogen Storage Disease Type II (GSD II)
- Glycogenesis 2 Acid Maltase Deficiency
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2008-08-08
- Last updated
- 2014-02-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00731081. Inclusion in this directory is not an endorsement.